Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- and carboxy-...

Full description

Bibliographic Details
Main Authors: Jason W Bennett, Anjali Yadava, Donna Tosh, Jetsumon Sattabongkot, Jack Komisar, Lisa A Ware, William F McCarthy, Jessica J Cowden, Jason Regules, Michele D Spring, Kristopher Paolino, Joshua D Hartzell, James F Cummings, Thomas L Richie, Joanne Lumsden, Edwin Kamau, Jittawadee Murphy, Cynthia Lee, Falgunee Parekh, Ashley Birkett, Joe Cohen, W Ripley Ballou, Mark E Polhemus, Yannick F Vanloubbeeck, Johan Vekemans, Christian F Ockenhouse
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-02-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC4769081?pdf=render

Internet

http://europepmc.org/articles/PMC4769081?pdf=render

Similar Items